CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein (Protein & Cell, 2017)
Shows embryo editing using Cas9 protein delivery and evaluates on-target efficiency, mosaicism, and off-target profiles in human zygotes.
All topicsGene editing (germline bans vs. permissive) · 3 peer-reviewed studies for, 7 against
Laboratory studies show germline (embryo) gene editing is technically feasible and can correct specific pathogenic variants in controlled settings, which is the core argument for eventual clinical use: preventing severe inherited disease before birth. However, the most policy-relevant question is not “can edits occur,” but whether heritable editing can be made predictably safe, accurate, and governable at population scale. The evidence base still highlights major technical hazards—mosaicism, unexpected mutations, and large deletions or complex rearrangements following double-strand breaks—any of which could create irreversible, heritable harm. In parallel, widely cited governance and ethics analyses argue that even if technical issues improve, consent, equity, enhancement pressures, and international coordination remain unresolved. Given the current state of risk and uncertainty, the evidence-weighted position is against clinical germline editing now and against broad permissive policy. A narrowly defined, tightly regulated research pathway (with strong oversight, transparency, and clear medical-necessity criteria) is more defensible than legalization for clinical reproduction at this stage.
Ranked by citation count.
Shows embryo editing using Cas9 protein delivery and evaluates on-target efficiency, mosaicism, and off-target profiles in human zygotes.
This peer-reviewed study examines how permissive germline editing policies risk violating human rights and exacerbating social inequalities. The paper proposes a Human Rights Impact Assessment framework to evaluate whether germline editing burdens disproportionately affect socially disadvantaged groups, addressing critical gaps in how societal consensus approaches to policy overlook existing power relations that create unfair advantages and disadvantages.
Shows embryo editing using Cas9 protein delivery and evaluates on-target efficiency, mosaicism, and off-target profiles in human zygotes.
Demonstrates technical feasibility of CRISPR editing in early human embryos while documenting challenges such as mosaicism and off-target effects.
Reports successful correction of a disease-causing mutation in human embryos with evidence of reduced mosaicism under specific experimental conditions.
This peer-reviewed study examines how permissive germline editing policies risk violating human rights and exacerbating social inequalities. The paper proposes a Human Rights Impact Assessment framework to evaluate whether germline editing burdens disproportionately affect socially disadvantaged groups, addressing critical gaps in how societal consensus approaches to policy overlook existing power relations that create unfair advantages and disadvantages.
Reports unexpected genomic changes associated with CRISPR-Cas9 editing, underscoring risks of unintended alterations relevant to heritable applications.
Calls for caution and governance, emphasizing ethical, societal, and safety concerns around heritable genome editing.
Finds CRISPR-induced breaks can produce large deletions and complex genomic rearrangements, challenging safety assumptions for clinical germline editing.
Systematic review of 223 publications identifying major ethical concerns about CRISPR germline editing. Found that high frequency of mutations jeopardizes safety and efficacy for both edited embryos and future offspring, with inadequate oversight and informed consent mechanisms.
Comprehensive analysis of technical challenges in human germline CRISPR-Cas9 editing including off-target effects, increased mosaicism, and unknown gene functions. Discusses ethical concerns and recommends further research on risks and potential benefits before clinical applications proceed.
This comprehensive review examines applications and barriers of CRISPR/Cas9 germline editing, emphasizing major technical obstacles including off-target mutagenesis, embryo mosaicism, low homology-directed repair efficiency, chromosomal rearrangements, and delivery challenges that currently preclude safe clinical translation of germline genome editing.
Yes, in laboratory settings. Studies have shown CRISPR editing is technically feasible in human embryos, and one reported correcting a pathogenic mutation with reduced mosaicism under specific experimental conditions.
Research highlights mosaicism, off-target effects, unexpected mutations, and large deletions or complex rearrangements caused by DNA double-strand break repair. Because the changes are inherited, these errors could affect future offspring.
Analyses point to unresolved issues around informed consent, equity and human rights, pressure toward enhancement, inadequate oversight, and the difficulty of coordinating rules internationally.
The current evidence supports against clinical germline editing and broad permissive policy at this stage. A narrowly defined research pathway with strong oversight, transparency, and clear medical-necessity criteria is considered more defensible.